How would you approach a patient who progressed on immunotherapy for merkel cell carcinoma?

This is an excellent question in a rare disease where we have clearly seen the use of immunotherapy leap to the forefront of management. Based on the Javelin II (previously treated patients) data, the FDA approved the use of Avelumab for patients with advanced MCC regardless of prior therapy in May ...